Hyderabad: Pharma giant Eli Lilly and Company (India) opened its new technology and innovation centre in Hyderabad's Hitech ...

There has been a 27% YoY increase in sales of weight-loss drugs, especially after the launch of Mounjaro and Novo Nordisk's ...

Lilly expands India presence with inauguration of Hyderabad site to accelerate global digital innovation: Our Bureau, Mumbai ...

Lilly intends to expand in India’s steadily increasing obesity and diabetes market. Zepbound hit 25,000 new prescriptions a week in the US in December 2023, just a month after the US Food and ...

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...

Sales of Danish drugmaker Novo Nordisk 's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month ...

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for market share, data from research firm Pharmarack showed on Monday.

U.S. drugmaker Eli Lilly expects to launch Mounjaro, its blockbuster diabetes drug and a wildly popular obesity treatment, in India as early as next year, CEO David Ricks told Reuters on Wednesday.

(Reuters) -Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.

FILE PHOTO: Vials of Eli Lilly's Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and weight loss, are seen in a fridge at a health clinic in Hyderabad, India, April 14, 2025.

Topline Eli Lilly on Tuesday said it will donate 400,000 tablets of its arthritis drug baricitinib—which has been shown to be effective in treating severe Covid-19 patients—to the Indian ...

Feb 28 (Reuters) - Eli Lilly LLY.N expects to launch its obesity drug tirzepatide in India as early as next year, the U.S. drugmaker's CEO David Ricks told Reuters on Wednesday.